title: Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates.
abstract: OBJECTIVE
  This study was designed to assess the effect of abciximab on platelet and leukocyte deposition 60 min after stent insertion in nonhuman primates.
  
  
  BACKGROUND
  Although it is well established that abciximab improves both short- and long-term clinical outcomes after stent placement, there have been no studies assessing its effect on early platelet and leukocyte deposition.
  
  
  METHODS
  Cynomolgus monkeys were pretreated with aspirin and either saline or a 0.4 mg/kg bolus of abciximab, and then subjected to angioplasty and Palmaz-Schatz stent placement in the common iliac artery or abdominal aorta. After 60 min, animals were euthanized and the stented artery was evaluated by immunohistochemistry and morphometry.
  
  
  RESULTS
  Complete occlusion of the stented vessel with a thin fibrin(ogen) meshwork and trapped blood occurred in two saline-treated and two abciximab-treated animals. In the four remaining saline-treated animals, a layer of erythrocytes trapped in a network of fibrin(ogen) was noted close to the vessel wall, and this was covered by a layer of large, irregular platelet thrombi. Leukocytes formed a monolayer on top of the platelets and near stent struts. In the four remaining abciximab-treated animals, the mean erythrocyte area was 65% smaller (p = 0.070), the platelet aggregate area was 89% smaller (p = 0.049) and the luminal area was 59% larger (p = 0.004). A monolayer of leukocytes also formed on top of the platelets and near stent struts.
  
  
  CONCLUSIONS
  In control stented blood vessels in this study, platelet thrombi formed not at the vessel wall, but on top of an erythrocyte-rich layer, and platelets recruited leukocytes. Abciximab decreased the size of platelet thrombi, but did not prevent leukocyte recruitment.
authors.affiliation: Istituto di Cardiologia, Policlinico S. Orsola, University of Bologna, Bologna, Italy.
authors.forename: Tullio
authors.initials: T
authors.lastname: Palmerini
authors.forename: Mark A
authors.initials: MA
authors.lastname: Nedelman
authors.forename: Lesley E
authors.initials: LE
authors.lastname: Scudder
authors.forename: Marian T
authors.initials: MT
authors.lastname: Nakada
authors.forename: Robert E
authors.initials: RE
authors.lastname: Jordan
authors.forename: Susan
authors.initials: S
authors.lastname: Smyth
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Gordon
authors.forename: John T
authors.initials: JT
authors.lastname: Fallon
authors.forename: Barry S
authors.initials: BS
authors.lastname: Coller
mesh_terms: D000077284:Abciximab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology*; D001012:Aorta, Abdominal / Q000473:pathology; D001158:Arteries / Q000187:drug effects / Q000293:injuries / Q000473:pathology*; D001792:Blood Platelets / Q000187:drug effects*; D007083:Iliac Artery / Q000473:pathology; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology*; D007150:Immunohistochemistry; D007962:Leukocytes / Q000187:drug effects*; D008252:Macaca fascicularis; D008854:Microscopy, Electron; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D015607:Stents / Q000009:adverse effects*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab